DMT Archives

Debra BorchardtOctober 25, 2023

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated N, N-dimethyltryptamine (“DMT“) program. “Following Cybin’s recent acquisition of Small Pharma Inc., our development programs are protected by 32 granted patents and over 170 pending applications, establishing our […]

Adam JacksonSeptember 27, 2023

The DMT drug appeared more effective when combined with SSRIs.

Adam JacksonSeptember 8, 2023

It also includes plant-derived DMT and mescaline.

Adam JacksonAugust 23, 2023

The company expects its current cash to fund it into 2026.

Debra BorchardtJune 5, 2023

Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)announced that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (DMT). AGN Neuro is the world’s first company to investigate DMT for both the treatment […]

Debra BorchardtMay 11, 2023

Psychedelic biotech company GH Research PLC (Nasdaq: GHRS) reported financial results for the first quarter that ended March 31, 2023. The company has no revenue at this time but did state that it has cash, and cash equivalents of $246.1 million down from $251.7 million at the end of 2022. The company said, “We believe […]

Adam JacksonMay 9, 2023

Parties exchanged legal barbs over religious freedom and the Controlled Substances Act.

Adam JacksonApril 26, 2023